Litigation Details for Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. (D. Mass. 2017)

« Back to Dashboard

Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. (D. Mass. 2017)

Docket		Date Filed	2017-05-31
Court	District Court, D. Massachusetts	Date Terminated	2018-07-31
Cause	35:271 Patent Infringement	Assigned To	Mark Lawrence Wolf
Jury Demand	Both	Referred To
Parties	CELLTRION HEALTHCARE CO., LTD.
Patents	8,367,649; RE38,551
Firms	Winston & Strawn LLP
Link to Docket	External link to docket

Details for Janssen Biotech, Inc. v. Celltrion Healthcare Co., Ltd. (D. Mass. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-31				External link to document
2017-05-31	316	Exhibit A	UCB”) own and/or license U.S. Patent No. RE38,551. The ’551 patent covers lacosamide, an anti-epileptic…551 patent. Appellants rely on the ’301 patent only for their argument that the ’551 patent is …obviousness-type double patenting. Like its parent ’729 patent, the ’301 patent claims compounds of …’301 patent and the asserted claims of the ’551 patent rendered the claims patentably distinct…a second patent not patentably distinct from the claims of the first patent.” Otsuka Pharm	External link to document
2017-05-31	33	Exhibit 6	Antitrust 8,367,649 Product liability…2017 31 July 2018 1:17-cv-11008 830 Patent Both District Court, D. Massachusetts	External link to document

Janssen Biotech v. Celltrion Healthcare Litigation Summary, 1:17-cv-11008

Last updated: August 7, 2026

Janssen Biotech’s litigation against Celltrion Healthcare concerned U.S. Patent No. 9,623,091, which claimed infliximab dosing methods for treating gastrointestinal disorders, including Crohn’s disease and ulcerative colitis. The case involved Celltrion’s Inflectra, the first FDA-approved infliximab biosimilar in the United States. A jury found the asserted claims valid and infringed, but the U.S. District Court for the District of Massachusetts entered judgment as a matter of law for Celltrion on obviousness. The Federal Circuit affirmed, leaving Janssen without an enforceable patent remedy against Celltrion under the ’091 patent. Janssen Biotech, Inc. v. Celltrion Healthcare Co., 76 F.4th 1293 (Fed. Cir. 2023).

What patents did Janssen assert against Celltrion in 1:17-cv-11008?

The central patent was U.S. Patent No. 9,623,091.

Item	Detail
Patent	U.S. Patent No. 9,623,091
Patent holder	Janssen Biotech, Inc.
Technology	Infliximab treatment and dosing regimens
Product at issue	Celltrion’s Inflectra, infliximab-dyyb
Court	U.S. District Court for the District of Massachusetts
Case number	1:17-cv-11008
Federal Circuit decision	76 F.4th 1293
Primary legal issue	Obviousness of the claimed infliximab dosing regimen
Final result	Celltrion prevailed on invalidity
Commercial effect	No injunction blocking Inflectra based on the ’091 patent

The asserted patent was not a composition-of-matter patent covering the infliximab antibody itself. It was a method-of-use patent directed to how infliximab is administered to patients with gastrointestinal diseases.

What did the ’091 patent claim?

The patent covered treatment regimens using an anti-TNF-alpha antibody, including infliximab, administered at specified doses and intervals. The claimed regimen generally tracked the loading and maintenance schedule used in the FDA-approved Remicade labeling for diseases such as Crohn’s disease and ulcerative colitis.

The legal dispute focused on whether the claimed regimen was an obvious optimization of known infliximab treatment protocols. The Federal Circuit held that the prior art, including clinical-trial disclosures and known treatment schedules, provided a sufficient basis for finding the claims obvious. Janssen Biotech, Inc. v. Celltrion Healthcare Co., 76 F.4th at 1300-1310.

What was the procedural history of Janssen v. Celltrion?

Case timeline

Date	Event
April 5, 2016	FDA approved Inflectra, infliximab-dyyb, for multiple indications
2017	Janssen filed the patent infringement action against Celltrion
2017-2021	Claim construction, fact discovery, expert discovery, and pretrial proceedings
Trial	Jury found the asserted patent claims not invalid and infringed
Post-trial	District court granted Celltrion judgment as a matter of law on obviousness
2023	Federal Circuit affirmed the invalidity judgment
Current legal effect	The ’091 patent cannot be used to block Celltrion’s Inflectra sales on the asserted claims

The case illustrates the difference between a jury verdict and the final judgment. The jury accepted Janssen’s infringement and validity positions. The district court later concluded that the evidence could not support the jury’s finding that the claims were nonobvious. The Federal Circuit affirmed that ruling.

Why did Celltrion prevail on obviousness?

Celltrion’s successful argument was that the claimed regimen did not contain a sufficiently inventive departure from the prior art.

The Federal Circuit focused on several points:

1. Infliximab was already known as an effective treatment for inflammatory gastrointestinal diseases.
2. The relevant dosing schedules were disclosed in clinical studies and treatment protocols.
3. The claimed dose and dosing intervals were predictable treatment parameters.
4. The prior art supplied a reasonable expectation that the regimen would work.
5. Janssen’s clinical evidence did not overcome the obviousness showing.

The appellate court rejected Janssen’s argument that uncertainty surrounding the precise dosing interval made the claims nonobvious. A dosing regimen can be obvious even when clinical development remains necessary, provided that the prior art gives a skilled artisan a reasonable expectation of success.

The decision applied the conventional obviousness framework under 35 U.S.C. § 103. It did not hold that all dosing patents are weak. It held that the particular infliximab regimen claimed in the ’091 patent was obvious in view of the record developed at trial. Janssen Biotech, Inc. v. Celltrion Healthcare Co., 76 F.4th at 1305-1310.

Did Celltrion infringe Janssen’s patent?

The jury found infringement. That finding did not control the final outcome because the patent was held invalid.

Infringement analysis focused on Celltrion’s proposed and commercial use of Inflectra under labeling that included dosing regimens corresponding to the asserted claims. Janssen relied in part on the relationship between the approved labeling and the patented method of treatment.

The invalidity judgment made the infringement finding commercially ineffective. An invalid patent cannot support damages or an injunction.

What was the final litigation outcome?

The final outcome favored Celltrion.

Judgment status

• The jury found the asserted ’091 claims valid and infringed.
• The district court granted Celltrion judgment as a matter of law that the asserted claims were obvious.
• The Federal Circuit affirmed the district court.
• Janssen did not obtain an enforceable injunction against Inflectra.
• Celltrion retained the ability to market Inflectra without the ’091 patent blocking the relevant indications or dosing regimen.

The Federal Circuit’s decision is the controlling appellate disposition of the case. It eliminated the principal patent-based litigation risk presented by the ’091 patent.

Was there a Paragraph IV challenge in this case?

No conventional Hatch-Waxman Paragraph IV framework governed the case.

Inflectra is a biologic product, not a small-molecule drug approved under an abbreviated new drug application. Celltrion pursued FDA approval under the Biologics Price Competition and Innovation Act pathway, which uses a biosimilar application rather than an ANDA Paragraph IV certification.

The litigation therefore proceeded under the BPCIA patent-dispute framework and ordinary patent infringement procedures. BPCIA cases can involve patent lists, information exchanges, and prelaunch litigation, but they do not use the same Orange Book Paragraph IV certification mechanism applicable to generic drugs.

What was the FDA status of Inflectra?

The FDA approved Inflectra, infliximab-dyyb, on April 5, 2016. Pfizer commercialized Inflectra in the United States, while Celltrion developed and supplied the product. FDA approval covered several Remicade reference-product indications, subject to the applicable biosimilar approval and extrapolation framework. (U.S. Food and Drug Administration, 2016a).

Product	Active ingredient	Sponsor or manufacturer	FDA status
Remicade	Infliximab	Janssen Biotech / Johnson & Johnson	Reference biologic
Inflectra	Infliximab-dyyb	Celltrion, commercialized by Pfizer	FDA-approved biosimilar
Renflexis	Infliximab-abda	Samsung Bioepis / Organon	Competing infliximab biosimilar
Avsola	Infliximab-axxq	Amgen	Competing infliximab biosimilar

Inflectra’s approval created direct competition with Remicade across multiple indications, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, depending on the approved labeling. (U.S. Food and Drug Administration, 2016a).

What was the exclusivity position for Remicade and Inflectra?

Remicade received the 12-year reference-product exclusivity period available to innovative biologics under the BPCIA. That regulatory exclusivity expired before the Janssen-Celltrion case reached its final appellate resolution.

FDA approval of Inflectra in 2016 meant that Celltrion entered the U.S. market before the expiration of all potentially relevant Remicade patent rights. Janssen’s litigation attempted to enforce the ’091 dosing patent against that entry.

The outcome shows that regulatory exclusivity and patent exclusivity operated separately:

Protection	Remicade position
FDA biologic exclusivity	Expired before final appellate disposition
Core antibody patent protection	Largely expired or nearing expiration by the biosimilar era
Dosing-method protection	Challenged through the ’091 litigation
Biosimilar approval	Inflectra approved in 2016
Final ’091 patent status	Invalidated for obviousness

Was the ’091 patent listed in the Orange Book?

No. Biologics such as Remicade are not listed in the Orange Book in the same manner as small-molecule drugs approved under the Federal Food, Drug, and Cosmetic Act.

The relevant patent information was handled through the BPCIA process and associated FDA biologics systems, including the Purple Book framework. The Orange Book is therefore not the correct source for determining the patent estate affecting Inflectra.

Were formulation patents at issue?

The case was not primarily a formulation-patent dispute.

The asserted ’091 patent concerned treatment methods and dosing. It did not principally claim a new infliximab formulation, excipient system, container, or manufacturing process. Formulation and manufacturing patents can create separate barriers in biologic competition, but the Federal Circuit’s decision in this case turned on the obviousness of the claimed clinical regimen.

For biosimilar risk assessment, the distinction matters:

• Composition patents protect the biologic molecule or antibody structure.
• Formulation patents protect the product’s excipients, concentration, stability, or presentation.
• Manufacturing patents protect cell culture, purification, or production methods.
• Method-of-use patents protect administration or treatment protocols.

Janssen’s asserted patent in this case was in the fourth category.

Did the case involve a settlement agreement?

The reported appellate decision does not establish a settlement resolving the ’091 patent dispute. The operative result was a judicial invalidity determination affirmed by the Federal Circuit.

The final decision should therefore be treated as a litigated invalidity outcome, not as a confidential launch settlement or negotiated license controlling Inflectra’s market entry.

What was the commercial significance for Janssen and Celltrion?

The judgment removed a major patent-based obstacle to Inflectra commercialization.

Janssen exposure

Janssen faced erosion of Remicade sales from:

• Inflectra;
• Renflexis;
• Avsola;
• hospital and payer-driven biosimilar substitution;
• discounts and contracting pressure;
• conversion of patients from reference infliximab to biosimilar products.

The invalidation of the ’091 patent reduced Janssen’s ability to use a dosing-method patent to delay or restrict biosimilar competition in the relevant indications.

Celltrion exposure

Celltrion avoided:

• a potential permanent injunction;
• lost U.S. sales of Inflectra;
• damages tied to the accused treatment regimen;
• additional launch restrictions;
• increased contracting uncertainty with Pfizer and U.S. providers.

The Federal Circuit ruling improved the durability of Inflectra’s U.S. commercial position, although it did not eliminate competition from other infliximab biosimilars or non-patent commercial barriers.

How strong was Janssen’s Remicade patent estate after the decision?

The estate was materially weaker after the ’091 invalidity ruling.

Patent category	Risk assessment after the case
Original infliximab composition protection	Limited by age and expiration
’091 dosing patent	Invalid against the asserted claims
Method-of-use patents	Subject to indication-specific claim scope and validity challenges
Formulation patents	Potentially relevant but not resolved by this case
Manufacturing patents	Potentially relevant to biosimilar developers
Regulatory exclusivity	Expired
Biosimilar launch barrier	Low relative to the prelaunch period

The decision also reduced the value of relying on broad clinical-regimen claims to protect a mature biologic. Such claims may be vulnerable when clinical protocols, loading schedules, and maintenance intervals are disclosed before the patent filing or are predictable from the development record.

What generic or biosimilar launch risks remained?

The ruling addressed the ’091 patent only. It did not automatically invalidate every patent Janssen or related entities might assert against an infliximab biosimilar.

Residual risks could include:

• separate method-of-use patents;
• formulation patents;
• manufacturing-process patents;
• patent claims held by third parties;
• state-law or contractual disputes;
• FDA labeling restrictions for non-covered indications;
• commercial risks from payer formulary placement;
• interchangeability and substitution rules;
• patent disputes involving other biosimilar sponsors.

For Celltrion, the decision substantially reduced the risk associated with the specific Janssen dosing patent. It did not create a blanket finding that all patents relating to infliximab were invalid or unenforceable.

How does this case compare with other infliximab biosimilar disputes?

The case is distinct because it centered on the clinical dosing regimen rather than on the antibody molecule itself.

Issue	Janssen v. Celltrion	Typical biosimilar patent dispute
Product	Inflectra	Biosimilar biologic
Asserted technology	Dosing method	Composition, formulation, process, or use
Regulatory pathway	BPCIA	BPCIA
Paragraph IV certification	Not applicable	Not applicable
Jury outcome	Valid and infringed	Varies
Final appellate outcome	Claims obvious and invalid	Depends on patent and record
Injunction	None after invalidity ruling	Case-specific

The case is particularly relevant to biosimilar developers because it demonstrates that a branded biologic sponsor can win a jury verdict and still lose on post-trial judgment when the patent claims an expected treatment schedule.

Key Takeaways

• Janssen asserted U.S. Patent No. 9,623,091 against Celltrion’s Inflectra.
• The patent covered infliximab treatment and dosing methods for gastrointestinal disorders.
• A jury found the patent claims valid and infringed.
• The district court overturned that result through judgment as a matter of law on obviousness.
• The Federal Circuit affirmed the invalidity ruling in 76 F.4th 1293.
• Celltrion obtained no final injunction blocking Inflectra under the ’091 patent.
• The case did not involve a conventional Hatch-Waxman Paragraph IV certification.
• The ’091 patent was a method-of-use patent, not primarily a formulation or manufacturing patent.
• The ruling weakened Janssen’s ability to use dosing claims to delay infliximab biosimilar competition.
• Separate patents and commercial barriers could still affect other infliximab biosimilar products.

FAQs About Janssen Biotech v. Celltrion

What drug was at issue in Janssen v. Celltrion?

The case involved Inflectra, Celltrion’s biosimilar to Janssen’s Remicade, both of which contain infliximab or an infliximab biosimilar version.

What patent number was litigated?

The principal asserted patent was U.S. Patent No. 9,623,091, covering infliximab treatment regimens.

Did Janssen win the jury trial?

Janssen won the jury’s infringement and validity findings, but Celltrion prevailed after the district court entered judgment as a matter of law that the asserted claims were obvious.

Did the Federal Circuit uphold Celltrion’s victory?

Yes. The Federal Circuit affirmed the district court’s invalidity ruling in 76 F.4th 1293.

Can Janssen use the ’091 patent to stop Inflectra sales?

No. The asserted claims were held invalid for obviousness, eliminating the patent as a basis for an injunction or damages against Celltrion under those claims.

References

1. Janssen Biotech, Inc. v. Celltrion Healthcare Co., 76 F.4th 1293 (Fed. Cir. 2023).

2. U.S. Food and Drug Administration. (2016a, April 5). FDA approves Inflectra, a biosimilar to Remicade. https://www.fda.gov

3. U.S. Patent No. 9,623,091. (2017). Methods of treating gastrointestinal disorders with anti-TNF-alpha antibodies. United States Patent and Trademark Office.

4. Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262(l).

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov